Gastrointestinal transit in cirrhotic patients: effect of hepatic encephalopathy and its treatment.
Chronic hepatic encephalopathy is highly responsive to changes in diet, to antibiotic therapy and to ingestion of nondigestible disaccharides. The precise pathophysiology of chronic hepatic encephalopathy in individual cases is highly variable, although ammonia toxicity and production of neurotransmitterlike substances in the gut have been proposed to contribute to the overall syndrome of chronic hepatic encephalopathy. The support for this hypothesis is based on the empiric observation that reduction in protein intake, a catharsis or both are effective treatments for chronic hepatic encephalopathy. This study was performed to evaluate the effect of mild subclinical and low-grade (grade 0 to 1) chronic hepatic encephalopathy on gastric emptying and oral-cecal transit times. Thirty patients were studied. Ten had no evidence of chronic hepatic encephalopathy, as determined with a battery of neuropsychiatric studies (group 1); 10 had subclinical hepatic encephalopathy, as judged on the basis of abnormal neuropsychiatric test performance but normal neurological examination (group 2); and 10 had grade 1 hepatic encephalopathy. Each underwent a liquid gastric emptying study and a lactulose oral-cecal transit time study. No significant differences between groups were evident in the results of the gastric emptying studies. In contrast, the time required for a lactulose load to reach the cecum was significantly greater in the patients with hepatic encephalopathy (p < 0.01) and increased as a function of the hepatic encephalopathy grade.(ABSTRACT TRUNCATED AT 250 WORDS)
Van Thiel
D H
DH
Oklahoma Transplantation Institute, Baptist Medical Center of Oklahoma, Oklahoma City 73112.
Fagiuoli
S
S
Wright
H I
HI
Chien
M C
MC
Gavaler
J S
JS
D000328:Adult; D000641:Ammonia / Q000378:metabolism; D002908:Chronic Disease; D004044:Dietary Proteins / Q000008:administration & dosage; D005260:Female; D005746:Gastric Emptying; D005772:Gastrointestinal Transit; D006501:Hepatic Encephalopathy / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use
D004044:Dietary Proteins; D000641:Ammonia; D009355:Neomycin